Thus, the phase II clinical study was planned to combine PSMA-specific CAR T-cells with moderate doses of IL-2 supplementation, which were found to be essential for CAR T-cell anti-tumor activities in the TME (69). This evidence concerns the gene IL2 and neoplasm.